Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms
Eli Lilly shares rose 0.2% after the FDA asked drugmakers to remove suicide-related warnings from GLP-1 weight-loss drugs. Lilly’s R&D chief said the company plans a rapid global launch of its oral obesity drug orforglipron, priced at $150 a month. Investors are watching for increased pill competition and the FDA’s upcoming decision.